HISTONE DEACETYLASE INHIBITOR
Beleodaq is a prescription medication approved by the Food and Drug Administration (FDA) to treat peripheral T-cell lymphoma (PTCL) that has relapsed or failed to respond to other drugs. Beleodaq is also referred to by its drug name, Belinostat.
Beleodaq is an anticancer drug. Beleodaq is a member of a class of drugs called histone deacetylase inhibitors. Beleodaq is believed to work by killing cancer cells and slowing their growth.
How do I take it?
Beleodaq is administered by intravenous injection on the first five days of a 21-day cycle.
Beleodaq comes in the form of a single-dose vial.
Side effectsread more
The FDA-approved label for Beleodaq lists common side effects including fatigue, fever, nausea, vomiting, and anemia (low red blood cell count).
Rare but serious side effects listed for Beleodaq include liver damage, dangerously low blood cell count, potentially fatal infections, fetal harm in pregnant women, and tumor lysis syndrome (a potentially fatal metabolic condition caused when many cancer cells die at the same time).
For more details about this treatment, visit:
Beleodaq – Spectrum
Treatment for Aggressive NHL Subtypes – Leukemia & Lymphoma Society